Thr770
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr770  -  DDX58 (human)

Site Information
DsILRLQtWDEAVFR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 17484200

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 2 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 2 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 2 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Relevant cell line - cell type - tissue:
HEK293T (epithelial) ( 2 ) , HUVEC (endothelial) ( 2 )

Upstream Regulation
Putative in vivo kinases:
CK2A1 (human) ( 2 )
Kinases, in vitro:
CK2A1 (human) ( 2 ) , DAPK1 (human) ( 1 )
Treatments:
DMAT ( 2 ) , okadaic_acid ( 2 ) , siRNA ( 2 ) , virus infection ( 2 )

Downstream Regulation
Effects of modification on DDX58:
enzymatic activity, inhibited ( 2 ) , molecular association, regulation ( 2 )
Inhibit interaction with:
DDX58 (human) ( 2 )

References 

1

Willemsen J, et al. (2017) Phosphorylation-Dependent Feedback Inhibition of RIG-I by DAPK1 Identified by Kinome-wide siRNA Screening. Mol Cell 65, 403-415.e8
28132841   Curated Info

2

Sun Z, et al. (2011) Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response. J Virol 85, 1036-47
21068236   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.